What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study

BACKGROUND: It is unclear what to do when people with type 2 diabetes have had no or a limited glycemic response to a recently introduced medication. Intra-individual HbA1c variability can obscure true response. Some guidelines suggest stopping apparently ineffective therapy, but no studies have add...

Descripción completa

Detalles Bibliográficos
Autores principales: McGovern, Andrew P., Dennis, John M., Shields, Beverley M., Hattersley, Andrew T., Pearson, Ewan R., Jones, Angus G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460517/
https://www.ncbi.nlm.nih.gov/pubmed/30979373
http://dx.doi.org/10.1186/s12916-019-1307-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460517/
https://www.ncbi.nlm.nih.gov/pubmed/30979373
http://dx.doi.org/10.1186/s12916-019-1307-8

Ejemplares similares